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Abstract
Thalidomide has reemerged as a promising anticancer and anti-inflammatory 
drug despite its devastating congenital birth defects. Many thalidomide 
derivatives with enhanced antiangiogenic and immunomodulatory effects 
or greater cytokine inhibition accompanied by less adverse toxicities than 
the parent drug have been developed. The mechanisms of action of tha-
lidomide and its analogs are complex and not yet fully understood, but 
studies indicate that their antiangiogenic and immunomodulatory effects 
play important roles. Thalidomide and lenalidomide have been approved 
for the treatment of multiple myeloma and myelodysplastic syndrome. The 
powerful antiangiogenic, anti-inflammatory, and apoptotic effects mean 
that thalidomide and its immunomodulatory derivatives will continue to 
be explored in the treatment of a variety of cancers and inflammatory 
diseases. [Tzu Chi Med J 2008;20(3):188–195]
Article Info
Article history:
Received: October 31, 2007
Revised: November 5, 2007
Accepted: November 20, 2007
Keywords:
Antiangiogenesis
Cytokines
Immunomodulatory drugs
Multiple myeloma
Thalidomide
1. Introduction
Thalidomide was initially marketed in Germany in 1956 
as a sedative and antiemetic for the treatment of 
morning sickness. It was widely introduced into clini-
cal practice in Europe, Australia, Canada, Japan, and 
other countries around the world due to its presumed 
low toxicity. The association between thalidomide 
and congenital birth defects, e.g., limb malformations, 
was first reported in 1961, and the drug was imme-
diately withdrawn from the market [see reference 1 
for a review of the history of thalidomide]. Interest-
ingly, thalidomide was never approved by the US Food 
and Drug Administration (FDA) because of concerns 
over its neuropathic effects.
The drug resurfaced in 1965 when it was discov-
ered serendipitously that the drug was remarkably 
effective in lessening the skin condition of patients 
with erythema nodosum leprosum [2]. But it was not 
until 1998 that the US FDA approved thalidomide for 
indications under strict patient guidelines. Its effects 
have been found to result from its immunomodulat-
ing and anti-inflammatory actions [3,4]. It has been 
suggested that the limb malformations might be sec-
ondary to the inhibition of vasculogenesis during limb 
bud development [5]. Consequently, the antiangiogenic 
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effect of thalidomide might be used to prevent the 
growth of blood vessels recruited by solid tumors. 
Indeed, thalidomide has been shown to inhibit basic 
fibroblast growth factor-mediated angiogenesis in a 
rabbit cornea micropocket model [5].
The broad spectrum of activities of thalidomide 
indicates that it may be used in a variety of clinical 
conditions, and further suggests that it probably exerts 
these effects through multiple mechanisms. Many clin-
ical trials using thalidomide and its derivatives as an-
ticancer agents have been conducted [6–9]. Here, we 
review the basic science, and focus primarily on the 
mechanisms of action of thalidomide and its deriva-
tives as anticancer agents. The enormous body of 
work on thalidomide and its derivatives precludes an 
exhaustive coverage of the literature.
2. Chemical properties and 
metabolism
Thalidomide consists of a racemic mixture of S(–) and 
R(+) enantiomers, with the former appearing to exert 
potent actions in immunomodulation (the reduction 
of tumor necrosis factor [TNF]-α release), sedation 
and teratogenicity, while the latter has also demon-
strated equally potent inhibition of TNF-α release from 
activated human mononuclear blood cells [10]. The 
rapid interconversion of the two enantiomers under 
physiological conditions renders its separation im-
practical, and further implies its potential teratogenic 
effect whenever thalidomide is prescribed. In an aque-
ous solution with a pH greater than 6, thalidomide 
undergoes rapid spontaneous hydrolysis into a pleth-
ora of degradation products which appear to be devoid 
of antiangiogenic activity [11].
Thalidomide is metabolized into five metabolites, 
each of which undergoes spontaneous hydrolysis into 
inactive products [11]. The metabolites appear to be 
generated by CYP2C19 with minor contributions from 
CYP2C9 and CYP1A1 [7]. None of the metabolites 
exhibited antiangiogenic activity in human models and 
only high concentrations of 5-hydroxythalidomide 
inhibited angiogenesis in a rat aortic ring assay [12]. 
Bauer et al [11] reported that the antiangiogenic and 
antiproliferative effects of thalidomide in a rat aorta 
model and human aortic endothelial cells, respec-
tively, were observed only with the addition of human 
or rabbit microsomes but not rat microsomes, indi-
cating that the metabolites rather than thalidomide 
per se were responsible for the pharmacological 
activities, including probably the teratogenic effects. 
However, the antiangiogenic activity of thalidomide in 
the absence of microsomes has also been suggested 
[7]. The relationship between biotransformation/
hydrolysis products and effects (or relevant mecha-
nisms of action) has been reviewed [13].
Although thalidomide exhibits serious teratogenic 
effects, it possesses significant immunomodulatory 
activities, especially the inhibition of TNF-α, and con-
siderable effort has been expended in the develop-
ment of analogs with reduced toxicities. Two classes 
of compounds have been developed using thalido-
mide as the template. Both classes of compounds 
exhibited potent inhibition of TNF-α but with differ-
ential cytokine modulation and T cell activation [14]. 
Immunomodulatory derivatives of thalidomide are 
termed IMiDs. Lenalidomide and actimid are two 
IMiDs. Lenalidomide has been approved by the FDA 
for the treatment of myelodysplastic syndrome with 
chromosome 5q31 deletion and multiple myeloma 
in 2005 and 2006, respectively. Actimid is being in-
vestigated for the treatment of myelodysplastic syn-
drome and myeloma. Still another group of derivatives, 
selected cytokine inhibitory drugs (SelCiDs), are being 
investigated for diverse clinical applications. An early 
[15] and several more recent reviews [6,9,16,17] 
on immunomodulation by these drugs have been 
published.
3. Mechanisms of action of thalidomide
3.1. Antiangiogenic activity
In 1971, Folkman formulated the hypothesis that 
tumor growth is dependent on angiogenesis [18]. 
Although the precise mechanisms of teratogenic ac-
tion of thalidomide remain unclear, the fact that limb 
bud formation depends heavily on angiogenesis led to 
the idea that teratogenic and antiangiogenic actions 
were related. Angiogenesis is the formation of new 
blood vessels from pre-existing microvessels through 
complex mechanisms that involve various growth fac-
tors, e.g., vascular endothelial growth factor (VEGF), 
basic fibroblast growth factor (bFGF) and platelet-
derived growth factor (PDGF) [19]. Initial studies de-
monstrated that thalidomide inhibited TNF-α-induced
angiogenesis in a rabbit cornea micropocket model 
[5] and inhibited microvessel formation in an isolated 
rat aorta model [11]. A more recent study using an 
in utero chicken embryonic chorioallantoic membrane 
(CAM) assay found that VEGF plus bFGF-induced ves-
sel formation was inhibited by thalidomide, and the 
antiangiogenic effect of thalidomide was increased 
by preincubation with human but not rat microsomes 
[20]. Furthermore, two putative hydroxylated thalido-
mides were found to exhibit antiangiogenic action in 
the CAM assay. The role of VEGF in tumor angiogenesis 
has been reviewed [21].
What are the molecular mechanisms of the antian-
giogenic action of thalidomide? Thalidomide has been 
found to inhibit TNF-α production from lipopolysac-
charide (LPS)-induced human monocytes and mouse 
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macrophages by increasing its mRNA degradation 
[22,23]. TNF-α has been observed to be a potent in-
hibitor of endothelial cell growth in vitro. The ang-
iogenic action of TNF-α in a rabbit cornea model was 
suggested to result from secondary inflammation 
mediated by leukocyte infiltration because, in this 
model system, a high dose of TNF-α did not suppress 
angiogenesis induced by bFGF, but instead stimulated 
neovascularization and exerted an inflammatory re-
sponse [24]. Further evidence suggested that pros-
taglandins [25], platelet-activating factor [26], and B61 
and its Eck receptor [27] may mediate TNF-α-induced
angiogenesis. Still, TNF-α may promote angiogenesis 
by upregulating the expression of endothelial integrin, 
which is crucial for angiogenesis [28]. It should be 
pointed out that TNF-α, by interacting with its recep-
tor, can activate a wide range of transcription factors 
and gene products, and consequently can directly in-
fluence a diverse spectrum of cellular activities [29]. 
TNF-α is considered a potential target in therapy for 
solid tumors. For example, TNF-α antagonists have 
been successfully developed for the treatment of 
inflammatory diseases and tumors [30].
Hypoxia-inducible factor 1α (HIF-1α) is a transcrip-
tion factor that senses reduced oxygen tension and 
responds with increased transcription of hypoxia-
inducible genes involved in angiogenesis. Accumula-
tion of HIF-1α protein but not its mRNA was induced 
by TNF-α in kidney cells via a nuclear factor (NF)-κB
dependent pathway [31]. Consequently, thalidomide 
may decrease the expression of HIF-1α, and hence 
the inhibition of angiogenesis, through reduction of 
TNF-α production [7]. NF-κB is an evolutionarily con-
served, inducible transcription factor that plays im-
portant roles in a very large variety of biological 
processes. It has been demonstrated that angiogen-
esis requires NF-κB activation [32]. The activity of 
NF-κB is controlled by an inhibitory protein, Ik-Bα.
Phosphorylation of Ik-Bα by IkB kinase leads to its 
degradation and allows active NF-κB to enter the nu-
cleus to activate gene transcription. Thalidomide has 
been shown to block NF-κB activity and cytokine-
mediated expression of NF-κB-regulated genes such as 
interleukin (IL)-8 through suppression of IkB kinase 
activity in human Jurkat T cell lymphocytes and hu-
man endothelial cell cultures [33,34]. Thus, thalido-
mide may regulate TNF-induced angiogenesis through 
suppression of the expression of VEGF, bFGF and IL-8. 
Furthermore, thalidomide has been demonstrated 
to inhibit endothelial cell proliferation in vitro, which 
appears to correlate with suppression of NF-κB activa-
tion [35]. It is important to mention that endothelial 
cells and VEGF are actively involved in vascular de-
velopment [19]. In addition, thalidomide and its ana-
logs have been observed to reduce NF-κB-dependent
HIV-1 replication in vitro in human monocyte-derived 
macrophages [36].
3.2. Immunomodulatory and 
anti-inflammatory activity
Inhibition of immune/inflammatory responses and 
angiogenesis by thalidomide is probably interrelated 
because cytokines such as TNF-α, and NF-κB have 
been found to be involved in both processes [33,34]. 
Thalidomide increased the levels of both intra- and 
extracellular IL-2 in cultures of human mononuclear 
cells activated with mitogens or antigen without af-
fecting proliferation or IL-2 receptors [37]. IL-2 may 
possess antitumor activity or may modulate the im-
mune system to induce anticancer activity. The serum 
level of TNF-α was reduced while that of interferon 
(IFN)-γ was increased in erythema nodosum leprosum 
patients following treatment with thalidomide [38]. 
In contrast to its suppressive effects in the inflamma-
tory response, thalidomide has been reported to act 
as a costimulator in enhancing the response of T cells 
to T-cell receptor complex, resulting in increased se-
cretion of IL-2 and IFN-γ and increased numbers of 
NK cells leading to enhanced cytotoxicity in multiple 
myeloma [39]. Under the condition of T cell costimu-
lation, thalidomide enhanced TNF-α generation by 
CD4+ and CD8+ T lymphocytes activated by anti-CD3, 
and elevated serum TNF-α levels in advanced cancer 
patients treated with an immunomodulatory derivative 
of thalidomide [40].
IL-12 plays an important role in the development 
of cellular immune responses. IL-12 stimulates IFN-γ
secretion and proliferation of activated T cells and 
NK cells, and enhances T and NK cell-mediated cyto-
toxicity [41]. Thalidomide inhibited IL-12 production 
by monocytes activated by LPS [42]. However, similar 
to TNF-α, IL-12 was increased by thalidomide and its 
analogs in vitro and in vivo under the condition of 
T cell activation [14,43]. IL-6 has been demonstrated 
to be a major growth factor for multiple myeloma 
[44]. The expression of IL-6 and its mRNA in mitogen-
activated blood mononuclear cells was selectively 
inhibited by thalidomide but the expression of IL-2, 
IL-4 and IL-10, which was markedly inhibited by dex-
amethasone, was unaffected [45]. However, levels of 
TNF-α, IL-1β and IL-6 were inhibited while IL-10 was 
largely increased by thalidomide in LPS-stimulated 
blood mononuclear cells [14]. IL-8 is a potent neu-
trophil chemoattractant that can be released from 
endothelial cells. Thalidomide enhanced the TNF-α-
induced but inhibited the LPS-induced IL-8 release 
from human umbilical vein endothelial cells [46].
Cyclooxygenase-2 (COX-2) is an important phar-
macological target in the treatment of pathological 
angiogenesis, including cancer and chronic inflam-
matory diseases [47]. In contrast to COX-1, which is 
constitutively expressed and plays a homeostatic role, 
COX-2 is an immediate early gene induced by many 
stimuli including LPS, cytokines and growth factors. 
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COX-2 has been reported to be required for endothe-
lial migration and rat corneal angiogenesis [48,49]. 
Thalidomide inhibited LPS-mediated induction of 
COX-2 protein and mRNA in murine macrophages by 
decreasing its mRNA stability without affecting its 
transcription [50]. This effect might partly explain the 
antiangiogenic activity of thalidomide.
The migration and invasion potentials of cancer 
cells play critical roles in tumor metastasis. Adhesion 
molecules facilitate the adherence of tumor cells to 
the endothelium and are required for the develop-
ment of metastasis. Blunting of TNF-α-induced up-
regulation of adhesion molecules (ICAM-1, VCAM-1, 
E-selectin) on human umbilical vein endothelial cells 
by thalidomide has been demonstrated [51]. Thalido-
mide also directly induced tumor cell apoptosis and 
G1 growth arrest in multiple myeloma cell lines and 
patient multiple myeloma cells that were resistant to 
anticancer drugs and dexamethasone [52]. Interest-
ingly, the effect of dexamethasone was enhanced by 
thalidomide and inhibited by IL-6 [52].
The multiple effects of thalidomide demonstrated 
both in vitro and in vivo, albeit more difficult to show 
in the former, include antiangiogenic, anti-inflammatory 
and immunomodulatory actions, downregulation of 
adhesion molecules, direct apoptotic effects and 
growth arrest. These effects suggest that the drug 
and its derivatives may be useful for the treatment of 
various diseases. Indeed, thalidomide and its deriva-
tives have been approved or are under clinical trials 
for a variety of diseases, including erythema nodosum 
leprosum, multiple myeloma, myelodysplastic syn-
drome, melanoma, prostate cancer, renal cell carci-
noma, Crohn’s disease, rheumatoid arthritis, Behcet’s 
disease, and many other diseases.
4. Immunomodulatory (IMiDs) and 
selective cytokine inhibitory 
(SelCiDs) thalidomide derivatives
To minimize the teratogenic effect and enhance the 
anti-TNF-α activity of thalidomide, two classes of de-
rivatives have been developed [14]. Both classes are 
much more potent TNF-α inhibitors than the parent 
drug thalidomide yet exhibit different pharmacologi-
cal spectra. One class has been found to be potent 
phosphodiesterase (PDE) 4 inhibitors that suppressed 
TNF-α production, exhibited a modest inhibitory effect 
on LPS-induced IL-1β and IL-12, modestly increased 
anti-inflammatory IL-10 generation, and did not affect 
IL-6 and T cell activation. These compounds appear 
to exhibit selective anti-inflammatory actions and are 
termed selected cytokine inhibitory drugs (SelCiDs). 
The other class did not inhibit PDE 4 but instead dem-
onstrated broad inhibitory effects on the LPS-mediated 
release of TNF-α, IL-1β, IL-6 and IL-12 while potently 
increasing IL-10 production. In addition to their strong 
anti-inflammatory effects, these compounds also po-
tently stimulated T cell proliferation as well as IL-2 and 
IFN-γ production. These compounds are termed IMiDs 
(immunomodulatory imide drugs). This review will 
focus on thalidomide and IMiDs, in particular lenalido-
mide (Revlimid, CC-5013), because the latter has been 
approved for the treatment of multiple myeloma and 
myelodysplastic syndrome and tested in many clinical 
trials for other diseases. The immunomodulatory and 
nonimmunomodulatory effects of these drugs will be 
presented and compared, if data are available.
4.1. Immunomodulatory effects
Thalidomide and IMiDs exert potent immunomodula-
tory properties including inhibition of TNF-α, IL-1β, IL-6, 
granulocyte macrophage-colony stimulating factor 
(GM-CSF), and stimulation of IL-10 in LPS-stimulated 
monocytes and macrophages. Lenalidomide and 
CC-4047 (Actimid) have been found to be up to 
50,000 times more potent TNF-α antagonists in LPS-
stimulated models than the parent compound [53,54]. 
Levels of IL-1β, IL-6 and GM-CSF were also inhibited 
whereas IL-10 was increased by lenalidomide and 
CC-4047, although with varying degrees of potency 
compared to thalidomide [14]. However, IMiDs may 
increase TNF-α production to potentiate immune re-
sponses under the condition of T cell activation. For 
example, CC-4047 increased TNF-α generation by 
CD4+ and CD8+ T lymphocytes stimulated by anti-CD3 
[40]. In a clinical trial, thalidomide increased plasma 
TNF-α level in patients with toxic epidermal necrolysis, 
and this was associated with increased mortality [55]. 
Similarly, lenalidomide has been found to increase 
TNF-α level in patients with metastatic melanoma 
without excess morbidity or mortality [56].
IL-12 plays an important role in the development 
of host immune response. IL-12 enhances the expan-
sion and activity of T and NK cells to boost innate 
and adaptive immunity [41]. IL-12 is produced pri-
marily by antigen-presenting cells (APC; monocytes, 
macrophages and dendritic cells) in T cell-dependent 
and -independent pathways. LPS directly stimulated 
T cell-independent IL-12 generation by APC, which 
was suppressed by thalidomide and IMiDs. In the 
T cell-dependent pathway, the production of IL-12 by 
the APCs was induced by the interaction of CD40 on 
the surface of the APC, with CD40L (CD40 ligand) 
on the surface of the activated T cells [57,58]. Analo-
gous to TNF-α, thalidomide and IMiDs exerted bidirec-
tional effects on IL-12 production. IL-12 production 
was suppressed by IMiDs in LPS-stimulated monocytes 
but stimulated by thalidomide and its analogs in vitro
and in vivo under the conditions of T cell stimula-
tion [14,43]. Thalidomide and IMiDs also upregulated 
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the expression of CD40L on the surface of T cells 
[14,43]. The time course of activation indicated that 
IL-12 production resulted from drug-induced T cell 
activation [43].
Expression of cell surface adhesion molecules plays 
important roles in response to inflammatory stimuli 
and cancer metastasis. Thalidomide was found to 
reduce the density of TNF-α-induced cell surface ad-
hesion molecules ICAM-1, VCAM-1 and E-selectin on 
human umbilical vein endothelial cells, and L-selectin 
on human leukocytes in vitro [51]. Blocking the ex-
pression of these molecules may partly explain the 
antivasculitic effect of thalidomide. Lenalidomide has 
been demonstrated to inhibit the binding of multiple 
myeloma cells to bone marrow stromal cells, result-
ing in reduced production of IL-6, VEGF and TNF-α,
blockade of angiogenesis, and stimulation of host 
anti-multiple myeloma NK cell immunity [39,52,59].
One of the major distinctive differences between 
IMiDs and SelCiDs is that the latter class of drugs 
exhibits little or no T cell activation. SelCiDs are PDE 
4 inhibitors, and increasing cAMP levels in T cells dur-
ing the early phase of mitogen or antigen activation 
results in a decreased proliferative potential [60]. 
In contrast, IMiDs are potent costimulators of T cells 
and increased cell proliferation in a dose-dependent 
manner [14]. Similar to thalidomide, these compounds 
exerted a greater effect on CD8+ cells than on CD4+
cells. When T cells were stimulated by anti-CD3, tha-
lidomide and IMiDs caused a marked increase in 
IL-2, IFN-γ and IL-12, and induced the upregulation of 
CD40L on the surface of T cells [14,43]. IMiDs are 100 
to 1000 times more potent than thalidomide in costim-
ulating T cells that have been partially activated by 
the T cell receptor complex [15]. IMiDs were demon-
strated to enhance T cell cytokine production through 
potentiation of the transcription factor AP-1 [61].
The multiple effects of thalidomide and IMiDs on 
the immune system reflect the intricacies of the in-
terplay among the myriad components participating 
in innate and adaptive immunity. Drugs that exhibit 
broad immunomodulatory activities are potential can-
didates for the treatment of various diseases. Major 
questions concerning the adverse profiles of these 
drugs will be presented below.
4.2 Nonimmunomodulatory effects
Thalidomide and IMiDs have been found to exert an-
tiangiogenic properties independent of their immu-
nomodulatory effects [5,62]. Using a novel in vitro
multicellular human umbilical vein endothelial cell 
culture and rat aorta assay, IMiDs and SelCiDs were 
shown to be significantly more potent than thalid-
omide in inhibiting angiogenesis. Furthermore, the 
antiangiogenic effect did not correlate with their TNF-α
and PDE 4 inhibitory efficacies [62]. In this study, an 
IMiD was observed to exhibit antitumor activity using 
a murine rectum polypoid carcinoma cell line xe-
nograft. The tumor growth rate was reduced and ac-
companied by extensive necrosis. IMiDs were more 
potent than thalidomide in reducing the microvessel 
density in murine lymphoma xenograft models [63]. 
It has been pointed out that in multiple myeloma, the 
close proximity interaction between bone marrow stro-
mal cells and patient multiple myeloma cells signifi-
cantly increases the levels of proangiogenic factor 
VEGF and IL-6 [6,39,52,59]. IL-6 is a major growth 
factor for multiple myeloma [44]. Thalidomide and 
CC-4047 (Actimid, an IMiD) significantly decreased the 
expression of VEGF and IL-6, leading to the inhibition 
of angiogenesis in multiple myeloma cells [59].
In addition to their direct antiangiogenic action, 
thalidomide and IMiDs inhibited, albeit modestly, DNA 
synthesis in human multiple myeloma cell lines and 
cells from patients [52]. IMiDs also inhibited the pro-
liferation of doxorubicin- and melphalan-resistant mul-
tiple myeloma cells by 20–50% [6,64]. Several studies 
have shown that thalidomide and IMiDs directly induce 
apoptosis or growth arrest in multiple myeloma cells 
[52], inhibit the generation of VEGF and IL-6 [59], 
and stimulate NK cell anti-multiple myeloma immu-
nity [39]. Another study showed that IMiDs activated 
caspase-8, enhanced multiple myeloma cell sensi-
tivity to Fas-induced apoptosis, and downregulated 
NF-κB activity as well as the expression of apoptosis 
inhibitory protein [65].
4.3. Adverse effects
Thalidomide was withdrawn from the market shortly 
after its introduction into clinical practice because of 
its teratogenic effects in babies born to women who 
took the drug during the first trimester of pregnancy. 
Neurologic adverse effects of thalidomide are com-
mon and often represent the limiting toxicity after 
repeated administration. Somnolence and constipa-
tion are dose-related, and peripheral neuropathy may 
occur following prolonged administration [66]. Tha-
lidomide may increase the risk of thromboembolic 
complications in cancer patients. The prevalence of 
thrombosis was about 5% with thalidomide mono-
therapy but increased about threefold when thalido-
mide was combined with corticosteroids or cytotoxic 
drugs [67]. Enoxaparin (40 mg, subcutaneous, qd) but 
not low dose warfarin (1 mg/day) reduced the inci-
dence of deep vein thrombosis (DVT) in a randomized 
trial of patients with multiple myeloma treated with 
thalidomide and chemotherapy [68].
Several phase I studies in patients with solid tumors 
or multiple myeloma showed that the toxicities asso-
ciated with lenalidomide, in contrast to thalidomide, 
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were primarily Grades 1 and 2 according to National 
Cancer Institute Common Toxicity Criteria. Sedation, 
somnolence, constipation and neuropathy were not 
reported [17]. Thrombocytopenia and neutropenia 
were found, but their occurrence was dose-limiting 
and developed during the second month of treatment. 
Interestingly, in a phase I study in patients with 
refractory or relapsed multiple myeloma, CC-4047 
(Actimid) appeared to retain some of the adverse ef-
fects of thalidomide, such as constipation, neuropa-
thy and DVT [69]. More importantly, lenalidomide has 
not been found to be teratogenic in rabbits, a sensi-
tive species for thalidomide-induced birth defects 
[16]. Thus, it appears that IMiDs, especially lenalido-
mide, lack the adverse effects of thalidomide or ex-
hibit reduced side effects. However, larger populations 
need to be evaluated to understand the frequency 
of adverse effects, and women of childbearing age 
taking these medications should take necessary 
measures to prevent conception.
5. IMiDs in cancer therapy
Given that IMiDs are potent inhibitors of monocyte 
inflammatory cytokine generation and angiogenesis, 
and are also strong costimulators of T cell activation, 
it is no wonder that these drugs have been widely 
tested in hundreds of clinical trials worldwide. Lenal-
idomide has been approved by the US FDA for the 
treatment of myelodysplastic syndrome and multiple 
myeloma. In addition, lenalidomide and Actimid 
alone or in combination with other therapeutic agents 
have been evaluated in melanoma, mantle cell carci-
noma, relapsed/refractory multiple myeloma, prostate 
cancer, renal cell carcinoma, and many other inflam-
matory diseases. For readers interested in clinical 
trials currently underway in the US, please refer to 
www.cancer.gov/clinicaltrials.
6. Conclusions
The serendipitous discovery of the anti-inflammatory 
effects of thalidomide has generated interest not only 
in understanding the mechanisms of thalidomide and 
its IMiDs but also in the application of these drugs for 
the treatment of cancers and inflammatory diseases. 
Studies have clearly demonstrated that IMiDs exhibit 
greater immunomodulatory and antiangiogenic effi-
cacy than the parent drug, and an apparent apop-
totic effect accompanied by a lack of thalidomide’s 
adverse effects, in particular teratogenicity. The IMiDs 
therefore exhibit novel mechanisms of anticancer 
activity and offer important alternatives for the treat-
ment of at least several cancers previously lacking 
appropriate drugs.
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